**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 10173**

**Columns:** **RESEARCH REPORT**

**miR-374b-5p suppresses RECK expression and promotes gastric cancer invasion and metastasis**

Xie J *et al.* miR-374b-5p in gastric cancer

Juan Xie, Zhi-Hui Tan, Xia Tang, Ming-Shu Mo, Yan-Ping Liu, Run-Liang Gan, Yi Li, Li Zhang, Guo-Qing Li

**Juan Xie, Zhi-Hui Tan, Xia Tang, Yan-Ping Liu, Li Zhang, Guo-Qing Li,** Department of Gastroenterology, the Second Affiliated Hospital of University of South China, Hengyang 421001, Hunan Province, China

**Juan Xie, Ming-Shu Mo, Run-Liang Gan, Yi Li,** Department of Diagnostics, Medical College of University of South China, Hengyang 421001, Hunan Province, China

**Author contributions:** Li GQ and Xie J designed the research; Li GQ, Xie J, Tan ZH and Tang X performed the experiments; Li GQ, Liu YP, Li Y, Gan RL and Zhang L provided the reagents/analytic tools; Li GQ, Xie J and Mo MS analyzed the data and wrote the paper.

**Supported by** National Natural Science Foundation of China No. 81071965

**Correspondence to:** **Dr. Guo-Qing Li,** Department of Gastroenterology, the Second Affiliated Hospital of University of South China, Jiefang Rd 30, Hengyang 421001, Hunan Province, China. ligq1970@163.com

**Telephone:** +86-734-8899681 **Fax:** +86-734-8899994

**Received:** March 17, 2014 **Revised:** June 23, 2014

**Accepted:** July 29, 2014

**Published online:**

**Abstract**

**AIM:** To profile expression of microRNAs (miRNAs) in gastric cancer cells and investigate the effect of miR-374b-5p on invasion and metastasis.

**METHODS:**A miRNA microarray assay was performed to identify miRNAs differentially expressed in gastric cancer cell lines (MGC-803 and SGC-7901) compared with a normal gastric epithelial cell line (GES-1). Upregulation of miR-374b-5p was newly identified and confirmed *via* quantitative real-time reverse-transcription PCR (qRT-PCR). MGC-803 cells were transfected with a synthesized anti-miR-374b-5p sequence or a control vector using Lipofectamine reagent, or treated with transfection reagent alone or phosphate-buffered saline as controls. Rate of transfection was verified after 48 h by qRT-PCR. Cells were then subjected to transwell migration, wound scratch and cell counting kit-8 assays. A bioinformatics analysis to identify miR-374b-5p target genes was performed using miRanda, PicTar and TargetScan software. A dual luciferase reporter assay was performed to evaluate the influence of miR-374b-5p on target gene activation, and qRT-PCR and western blotting were used to evaluate the levels of target mRNA and protein following transfection with miR-374b-5p antisense oligonucleotides.

**RESULTS:** The microarray profiling revealed a downregulation of 14 (fold change < 0.667; *P* < 0.05) and upregulation of 12 (fold change > 1.50; *P* < 0.05) miRNAs in MGC-803 and SGC-7901 cells compared with GES-1 controls. The upregulation of miR-374b-5p (fold change = 1.75 and 1.64 in MGC-803 and SGC-7901, respectively; *P* < 0.05) was confirmed by qRT-PCR. Compared with the control groups, the restoration of miR-374b-5p expression with anti-miR-374b-5p significantly suppressed the metastasis, invasion and proliferation of MGC-803 cells. The bioinformatics analysis predicted that the 3’ untranslated region (UTR) of eversion-inducing cysteine-rich protein with Kazal motif (RECK) contains three miR-374b-5p target sequences. RECK was verified as a target gene in a dual luciferase reporter assay showing that activation of RECK 3'UTR-pmirGLO was increased by co-transfection with miR-374b-5p. Finally, transfection of miR-374b-5p antisense oligonucleotides increased mRNA and protein levels of RECK in MGC-803 cells (*P* < 0.05).

**CONCLUSION:** These findings indicate that upregulation of miR-374b-5p contributes to gastric cancer metastasis and invasion through inhibition of RECK expression.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Gastric cancer; microRNAs microarray; miR-374b-5p; RECK; Invasion and metastasis

**Core tip:** Abnormal expression of microRNAs (miRNAs) is one of the key mechanisms in cancer development, invasion and metastasis. The results of this study identify aberrant expression of 26 miRNAs in two human gastric cancer cell lines, which included upregulation of miR-374b-5p. The invasive and metastatic ability of cancer cells was decreased by transfection of miR-374b-5p antisense oligonucleotides. Furthermore, eversion-inducing cysteine-rich protein with Kazal motif was identified as a target of miR-374b-5p. These data suggest that miR-374b-5p may be a potential biomarker and diagnostic tool for gastric cancer classification and diagnosis.

Xie J, Tan ZH, Tang X, Mo MS, Liu YP, Gan RL, Li Y, Zhang L, Li GQ. miR-374b-5p suppresses RECK expression and promotes gastric cancer invasion and metastasis. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Human gastric cancer is the fourth most common malignancy in the world, with 934000 new cases occurring each year; unfortunately, the overall five-year survival rate remains below 20%[[1](#_ENREF_1)]. The poor prognosis is in part due to tumor invasion and metastasis, with contributions from abnormalities in tumor intracellular signaling pathways[[2](#_ENREF_2)]. Signaling molecules, such as matrix metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth factor, have been shown to affect tumor metastasis[[3](#_ENREF_3)]. It has been hypothesized that the dysregulation of these signaling pathways results from mutations in genes coding for these molecules and their interactions with environmental factors[[1](#_ENREF_1)]. However, recent studies indicate that abnormal expression of microRNAs (miRNAs) is also an important factor[[4](#_ENREF_4)].

miRNAs are a class of small non-coding RNA molecules approximately 22 nucleotides in length that are widely expressed in many organisms[[5](#_ENREF_5)]. miRNAs bind to partially complementary sites on target mRNAs to promote their degradation or inhibit translation[[6](#_ENREF_6)]. More than half of the human miRNA genes are located at tumor-related chromosomal loci[[4](#_ENREF_4)], and recent studies have identified altered regulation of many miRNAs in gastric cancer. For example, miR-20[[7](#_ENREF_7)], miR-34b[[8](#_ENREF_8)], miR-128[[9](#_ENREF_9)] and miR-21[[10](#_ENREF_10)] are abnormally expressed during gastric carcinoma induction, while miR-15, miR-16[[11](#_ENREF_11)], miR-372[[12](#_ENREF_12)] and miR-143[[13](#_ENREF_13)] can affect the apoptosis and drug resistance of gastric cancer cells, and miR-218[[14](#_ENREF_14)], miR-141[[15](#_ENREF_15)], mir-375[[16](#_ENREF_16)], miR-101[[17](#_ENREF_17)] and miR-25[[18](#_ENREF_18)] contribute to tumor differentiation, invasion and metastasis. Thus, further investigation of aberrant miRNA expression could aid in the development of novel strategies for gastric cancer prevention, diagnosis and treatment. In the current study, miRNA expression in gastric cancer cell lines was profiled in order to reveal new miRNAs for further clinical applications. Furthermore, the role of miR-374b-5p (a newly identified aberrantly expressed miRNA) in cancer cell invasion and metastasis was investigated.

**MATERIALS AND METHODS**

***Cell lines and culture***

The human gastric carcinoma cell line MGC-803, provided by the Cell Bank of Chinese Academy of Sciences (Shanghai, China), was cultured in RPMI-1640 medium. The human gastric adenocarcinoma cell line SGC-7901 and the normal human gastric epithelial cell line GES-1 were provided by the Cell Bank of Xiangya Central Laboratory at Central South University (Changsha, Hunan, China) and cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Hyclone of Thermo Fisher Scientific Inc., Waltham, MA, United States). All cell lines were cultured at 37°C with 5% CO2 in media containing 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma-Aldrich, St Louis, MO, USA) and 10% fetal bovine serum (FBS; Invitrogen of Thermo Fisher Scientific Inc.).

***RNA isolation and miRNA microarray profiling***

Total cellular RNA was isolated from cultured cells using Trizol reagent (Invitrogen) and purified with an RNeasy Mini kit (Qiagen, Hilden, Germany). The RNA samples were labeled with a MiRCURY Array Power Labeling kit (Exiqon, Vedbaek, Denmark) and used as probes for hybridization in a Hybridization Chamber II (Ambion of Thermo Fisher Scientific Inc.). Hybridized miRNA microarrays were scanned on a GenePix 4000B microarray scanner and analyzed with GenePix Pro software V6.0 (Molecular Devices, Sunnyvale, CA, United States). MeV software (V4.6, TIGR) was used to analyze the differential miRNA expression (fold change > 1.50 or ratio < 0.667) and differential expression was confirmed by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR).

***qRT-PCR***

Total cellular RNA was reverse transcribed using a Hairpin-it miRNA qPCR Quantitation kit (GenePharma, Shanghai, China). Amplification conditions were 95°C for 3 min followed by 40 cycles of 95°C for 30 s and 62°C for 40 s using primers obtained from GenePharma: miR-374b-5p (80 bp), 5'-TCAGCGGATATAATACAACCTGC-3' and 5'-TATCGTTGTTCTCCACTCCTTCAC-3'; reversion-inducing cysteine-rich protein with Kazal motifs (RECK) (90 bp), 5'-TCTGATGGCTGGGTTGGCTTAG-3' and 5'-ATCATTCTTTGAAGATGCCTGCTTG-3'; U6 (70 bp, used as an internal control), 5'-ATTGGAACGATACAGAGAAGATT-3' and 5'-GGAACGCTTCACGAATTTG-3'; and β-actin (70 bp, used as an internal control), 5'-CCCTGGCACCCAGCAC-3' and 5'-AGTCCTTCCACGATACCAAAGT-3'.

***Antisense oligonucleotide transfection***

MGC-803 cells were seeded in six-well plates and cultured with Lipofectamine 2000 transfection reagent (Invitrogen) and vectors (20 nmol/L) containing negative control (5'-CAGUACUUUUGUGUAGUACAA-3') and anti-miR-374b-5p (5'-CACUUAGCAGGUUGUAUUAUAU-3') sequences, according to the manufacturer’s protocol. The control conditions included untreated (phosphate-buffered saline only), transfection reagent only, and transfection with the negative control vector. The transfection rate after 48 h was confirmed by qRT-PCR.

***Cell counting kit -8 cell viability assay***

Cells from each group (untreated, transfection reagent only, control vector, and anti-miR-374b-5p) were added to 10 µL of Cell counting kit (CCK)-8 solution (Yiyuan Biotech, Guangzhou, China) and incubated at 37°C in 5% CO2 for 1 h according to the manufacturer's protocol. An Elx-800 enzyme-linked immunoassay analyzer (Bio-Tek, Winooski, VT, United States) was used to measure the optical densities at 450 nm. The average and standard deviation of absorbances in each group were presented as a histogram.

***Transwell tumor cell invasion assay***

Cells from each group (untreated, transfection reagent only, control vector, and anti-miR-374b-5p) were plated on transwell chambers (PengBo Biotech, Changsha, China) coated with Matrigel Basement Membrane Matrix (BD Biocoat; Becton, Dickenson and Co., Franklin Lakes, NJ, United States) according to the manufacturer's protocol. The upper chamber contained the plated cells in 100 μL of media, whereas the lower chamber contained 500 μL of DMEM with 20% FBS. After 48 h, the cells remaining on the upper side of the membrane were cleared, and the invaded cells on the lower side of the membrane were fixed and stained with Coomassie Brilliant Blue. The number of cells from five random microscopic fields was quantified for each group.

***Wound scratch assay***

Cells from each group (untreated, transfection reagent only, control vector, and anti-miR-374b-5p) that were seeded on a six-well plate were scraped with a 100 μL pipette tip to create two linear regions devoid of cells. Cells were stained with Coomassie Brilliant Blue and the scratch distance between the two linear regions was imaged and measured at different time points using ImagePro 6.0 (Media Cybernetic, Rockville, MD, United States). Five random non-overlapping images in each well were selected and quantitated for statistical analysis.

***Dual luciferase reporter assay***

MGC-803 cells were co-transfected with RECK 3'UTR-pmirGLO plasmid and a miR-374b-5p mimic or hsa-miR-NC vector using Lipofectamine 2000 according to the manufacturer’s instructions. After 48 h, luciferase activity was detected on a Glomax 20/20 luminometer using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, United States). For this assay, relative activity was defined by the ratio of firefly to renilla luciferase activity. Statistical analyses were then performed using: Δ luciferase activity = relative activity with miR-374b-5p/relative activity with hsa-miR-NC.

***Protein extraction and western blotting***

Total cellular protein was extracted using RIPA buffer (Beyotime Biotech, Shanghai, China) and samples were separated *via* 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Beyotime Biotech). After blocking with 3% bovine serum albumin, the membranes were blotted overnight with a primary antibody against RECK (1:1000; Proteintech Group, Chicago, IL, United States) or GAPDH (1:3000; Sigma-Aldrich), and incubated with a secondary antibody (1:5000; Jackson ImmunoResearch, West Grove, PA, United States). Protein bands were visualized with enhanced chemiluminescence (Thermo Fisher Scientific Inc.) and imaged and analyzed with Alphalmager 2200 image software (UVP, Upland, CA, United States).

***Statistical analysis***

All statistical analyses were performed using SPSS 16.0 statistical software (SPSS, Chicago, IL, United States). One-way ANOVA and least significant difference tests were used to investigate the difference between groups with *P* < 0.05 indicating statistical significance. Data are presented as mean ± standard deviation.

**RESULTS**

***Expression of miR-374b-5p in gastric cancer cells***

Fourteen miRNAs were significantly reduced in gastric cancer cells (MGC-803 and SGC-7901) compared to normal gastric epithelial cells (GES-1), including hsa-miR-20b-5p, ebv-miR-BART19-3p, hsa-miR-33a-5p, hsa-miR-33b-5p, hsa-miR-196b-5p, hsa-miR-4308, hsa-miR-106b-3p, kshv-miR-K12-5\*, hsa-miR-106b-5p, hsa-let-7f-5p, hsa-miR-7-5p, hsa-miR-24-1-5p, hsa-miR-185-5p and hsa-miR-1321 (ratio < 0.667, *P* < 0.05) (Figure 1A). In contrast, 12 miRNAs were increased in MGC-803 and SGC-7901 cell lines, including hsa-miR-1290, hsa-miR-2115-3p, hsa-miR-3607-3p, hsa-miR-182-5p, hsa-miR-138-1-3p, hsa-miR-222-3p, hsa-miR-937, hsa-miR-100-5p, hsa-miR-20a-5p, hsa-miR-3653 and hsa-miR-191-5p (ratio > 1.50, *P* < 0.05). The expression of hsa-miR-374b-5p was increased by fold changes of 1.75 and 1.64 in MGC-803 and SGC-7901 cells, respectively (Figure 1B), which was further confirmed via qRT-PCR (Figure 1C).

***miR-374b-5p inhibition of gastric cancer cell metastasis and invasion***

To examine the function of upregulated miR-374b-5p in cancer cells, expression was suppressed in MGC-803 cells with antisense oligonucleotides (confirmed by qRT-PCR; data not shown). Compared to the control groups, the anti-miR-374b-5p group showed a significant reduction in transwell invasion after 48 h (Figure 2A). A scratch assay to evaluate tumor cell metastasis ability revealed that suppression of miR-374b-5p expression inhibited cell migration into the barren substratum (Figure 2B). Furthermore, the proliferation of MGC-803 cells as assessed by the CCK-8 assay was suppressed by miR-374b-5p antisense, which was statistically significant 96 h after transfection (Figure 2C).

***Regulation of RECK expression by miR-374b-5p***

To identify the effect of miR-374b-5p on gene regulation in gastric cancer cells, a bioinformatics analysis was performed to predict direct tumor development targets. miRanda (http://www.microrna.org/microrna/home.do), PicTar (http://pictar.mdc-berlin.de) and TargetScan (http://www.targetscan.org) software revealed that *RECK*, a gene involved in tumor metastasis and angiogenesis, contains three target sequences for miR-374b-5p in the 3’ untranslated region (UTR) (Figure 3A). This was confirmed by a dual luciferase reporter assay showing that co-transfection with miR-374b-5psignificantly reduced RECK-driven luciferase activity (Figure 3B). Moreover, RECK protein and mRNA levels were increased in cells transfected with miR-374b-5p antisense oligonucleotides (*P* < 0.05) (Figure 3C, D).

**DISCUSSION**

Many miRNAs have expression patterns that are unique within certain cancer tissues[19]. miR-222-3p is upregulated in endometrial carcinoma, promoting proliferation and invasion, but downregulated in prostate cancer[20,21]. Some researchers suggest that these miRNA expression characteristics are potential biomarkers and powerful diagnostic tools for tumor classification and diagnosis[19]. Therefore, we profiled miRNA expression in gastric cancer, comparing two cancer cell lines with normal mucosal cells. From this analysis, we identified upregulation of miR-374b-5p and determined that it is involved in tumor metastasis and invasion. Furthermore, we confirmed that a target of miR-374b-5p is the 3’ UTR of *RECK*, which has been implicated in tumor metastasis and angiogenesis[[2](#_ENREF_19)2], and that suppression of miR-374b-5p activity increases the expression of RECK mRNA and protein. These results suggest a role of aberrant miR-374b-5p upregulation and an underlying molecular mechanism in gastric cancer progression.

Aberrant expression of various miRNAs are associated with carcinogenesis and cancer progression, and can therefore serve as efficient diagnostic biomarkers for analyses of histologic type, drug resistance and clinical prognosis[[23](#_ENREF_21),[24](#_ENREF_22)]. Evaluation of the expression of 200 miRNAs is sufficient to molecularly classify human cancers and may help in the assessment of clinical diagnosis and treatment[[23](#_ENREF_23),25]. However, the miRNA expression profile of gastric cancer is not well defined. The analyses presented here identified upregulation of 12 and downregulation of 14 miRNAs in two gastric cancer cell lines. Many of these findings were consistent with previous reports concerning the upregulation of miR-1290[[26](#_ENREF_24)], miR-182-5p[[27](#_ENREF_25)], miR-138-1-3p[[28](#_ENREF_26)], miR-20a-5p[[29](#_ENREF_27)], miR-100-5p[30] and miR-191-5p[31] and the downregulation of miR-33a-5p[[32](#_ENREF_30)], miR-33b-5p[[32](#_ENREF_30)], miR-4308[[33](#_ENREF_31)], kshv-miR-K12-5\*[[34](#_ENREF_32)], miR-106b-5p[[35](#_ENREF_33)], let-7f-5p[31] and miR-7-5p[[36](#_ENREF_34)]. However, our results differ from reports on miR-222-3p[30], miR-937[[37](#_ENREF_35)], miR-185-5p[[38](#_ENREF_36)], miR-3607-3p[[39](#_ENREF_37)], miR-3653[40], miR-20b-5p[[38](#_ENREF_36)], miR-106b-3p[41], ebv-miR-BART19-3p[[42](#_ENREF_40)], miR-196b-5p[[43](#_ENREF_41)] and miR-1321[[39](#_ENREF_37)], possibly due to differences in cell lines, cancer cell differentiation, or the screening criteria for miRNA. There have been no previous reports regarding gastric cancer and expressions of miR-24-1-5p, miR-2115-3p, or miR-374b-5p, which was selected for further study.

We previously reported that downregulation of miR-7 in gastric cancer affects tumor metastasis, though antisense treatment did not completely inhibit the metastasis of cancer cells[44], suggesting that other miRNAs may also be involved. This study shows that miR-374b-5p expression was significantly upregulated in SGC-7901 cells, and to a greater extent in MGC-803 cells. Furthermore, the adherence, migration, and invasion of MGC-803 cells were decreased significantly after suppression of miR-374b-5p expression. Abnormal miR-374b-5p expression in luminal-HER2-positive breast cancer cells can be used for classifying clinicopathologic subtypes of breast cancer[[35](#_ENREF_33)], and its upregulation in blood may be an underlying diagnostic molecular marker for invasive urinary bladder cancer[[45](#_ENREF_42)]. Combined, these data indicate that miR-374b-5p plays an important role in tumorigenesis within different cancers.

After demonstrating the effects of miR-374b-5p on gastric cancer cell growth and migration, we identified a functional target through bio-informatics analysis and dual luciferase reporter assays. The results suggest that miR-374b-5p can bind to the 3’ UTR of *RECK* and consequently downregulate its expression. Previous studies have shown that RECK is a membrane-anchored glycoprotein that binds and negatively regulates a number of MMPs, included MMP-2 and MMP-9[22,[46](#_ENREF_43)]. MMPs proteolytically degrade extracellular matrix proteins, which is critical for tumor metastasis and invasion[22]. Clinical research indicates that *RECK* expression negatively correlates with invasion-related clinicopathologic factors in hepatocellular carcinoma[[47](#_ENREF_44)] and breast cancer[[35](#_ENREF_33)], and tumorous tissues with higher RECK mRNA expression are less invasive and associated with better patient survival[[48](#_ENREF_45)]. Some miRNAs, such as miRNA-222[[49](#_ENREF_46)] and miRNA-221[50], have been shown to regulate *RECK* expression and affect tumor invasion and metastasis. The results of the present study indicate that miR-374b-5p also can post-transcriptionally suppress RECK expression and thus promote the invasion and metastasis of gastric cancer cells. Future studies will be performed to verify this regulation in animal models of gastric cancer and investigate the relative mechanism.

In conclusion, the results of this study demonstrate that human gastric cancer cells have significant alterations of miRNA expression, including upregulation of miR-374b-5p. Furthermore, miR-374b-5p can facilitate the invasion and metastasis of gastric cancer cells, likely through inhibition of RECK expression.

**COMMENTS**

***Background***

MircroRNAs (miRNAs) play an important role in the post-transcriptional regulation of gene expression and human carcinogenesis. Although there have been significant advances, the function of miRNAs in gastric cancer still needs further research.

***Research frontiers***

Abnormal expression of miR-374b-5p has been reported in luminal-HER2-positive breast cancer cells and invasive urinary bladder cancer. However, little is known about the expression and mechanism of miR-374b-5p as a metastasis-promoting factor in gastric cancer.

***Innovations and breakthroughs***

This study profiles the expression of, and identifies significantly altered, miRNAs in two human gastric cancer cell lines. The results suggest that upregulation of miR-374b-5p facilitates the invasion and metastasis of gastric cancer cells, and identifies inhibition of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) as a possible molecular mechanism.

***Applications***

miR-374b-5p may be a potential biomarker and powerful diagnostic tool for gastric cancer classification and diagnosis.

***Terminology***

RECK is a membrane-anchored glycoprotein that binds and negatively regulates a number of matrix metalloproteinases that break down the extracellular matrix.

***Peer review***

This study investigated the alterations of miRNA expression in gastric cancer cells and found that upregulation of miR-374b-5p regulates the invasion and metastasis of cancer cells. Moreover, RECK was identified as a target of miR-374b-5p, which indicates a mechanism for the tumorigenic effects. These results are interesting and suggest that miR-374b-5p may be a potential biomarker and diagnostic tool in gastric cancer.**REFERENCES**

1 **Shah MA**, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. *J Natl Compr Canc Netw* 2010; **8**: 437-447 [PMID: 20410336]

2 **Deng N**, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. *Gut* 2012; **61**: 673-684 [PMID: 22315472 DOI: 10.1136/gutjnl-2011-301839]

3 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

4 **Calin GA**, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006; **6**: 857-866 [PMID: 17060945]

5 **Shenouda SK**, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? *Cancer Metastasis Rev* 2009; **28**: 369-378 [PMID: 20012925 DOI: 10.1007/s10555-009-9188-5]

6 **Cifuentes D**, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND, Wolfe SA, Giraldez AJ. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. *Science* 2010; **328**: 1694-1698 [PMID: 20448148 DOI: 10.1126/science.1190809]

7 **Sacconi A**, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. *Cell Death Dis* 2012; **3**: e423 [PMID: 23152059 DOI: 10.1038/cddis.2012.160]

8 **Tsai KW**, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, Huang KH, Chan WC, Lin WC. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. *Int J Cancer* 2011; **129**: 2600-2610 [PMID: 21960261 DOI: 10.1002/ijc.25919]

9 **Yasui W**, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular pathology of gastric cancer: research and practice. *Pathol Res Pract* 2011; **207**: 608-612 [PMID: 22005013 DOI: 10.1016/j.prp.2011.09.006]

10 **Chan SH**, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. *Anticancer Res* 2008; **28**: 907-911 [PMID: 18507035]

11 **Xia L**, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. *Int J Cancer* 2008; **123**: 372-379 [PMID: 18449891 DOI: 10.1002/ijc.23501]

12 **Cho WJ**, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. *Mol Cells* 2009; **28**: 521-527 [PMID: 19937137 DOI: 10.1007/s10059-009-0158-0]

13 **Zhang P**, Zhang J, Wang C, Liu C, Wang H, Li Z. Highly sensitive and specific multiplexed microRNA quantification using size-coded ligation chain reaction. *Anal Chem* 2014; **86**: 1076-1082 [PMID: 24364819 DOI: 10.1021/ac4026384]

14 **Tie J**, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y, Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. *PLoS Genet* 2010; **6**: e1000879 [PMID: 20300657 DOI: 10.1371/journal.pgen.1000879]

15 **Du Y**, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. *J Gastroenterol* 2009; **44**: 556-561 [PMID: 19363643 DOI: 10.1007/s00535-009-0037-7]

16 **Ding L**, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. *Cell Res* 2010; **20**: 784-793 [PMID: 20548334 DOI: 10.1038/cr.2010.79]

17 **Wang HJ**, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Tao HQ. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. *Eur J Cancer* 2010; **46**: 2295-2303 [PMID: 20712078 DOI: 10.1016/j.ejca.2010.05.012]

18 **Zhao H**, Wang Y, Yang L, Jiang R, Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. *Mol Cell Biochem* 2014; **385**: 207-213 [PMID: 24078004 DOI: 10.1007/s11010-013-1829-x]

19 **Wang D,** Qiu C, Zhang H, Wang J, Cui QH, Yin YX. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. *PLoS One* 2010; **9**: e13067 [DOI: 10.1371/journal.pone.0013067]

20 **Tsuchiyama K,** Ito H, Taga M, Naganuma1 SJ, Oshinoya Y, Nagano J, Yokoyama O, Itoh H. Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. *Prostate* 2013; **73**: 827-834 [PMID: 23184537 DOI: 10.1002/pros.22626]

21 **Liu BY,** Che Q, Qiu HF, Wei B, Chen XY, Lu W, Li BL, Wan XP. Elevated MiR-222-3p Promotes Proliferation and Invasion of Endometrial Carcinoma via Targeting ERα. *PLoS One* 2014; **9:** e87563 [DOI: 10.1371/journal.pone.0087563]

22 **Du YY**, Dai DQ, Yang Z. Role of RECK methylation in gastric cancer and its clinical significance. *World J Gastroenterol* 2010; **16**: 904-908 [PMID: 20143471]

23 **Shah MA**, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Molecular classification of gastric cancer: a new paradigm. *Clin Cancer Res* 2011; **17**: 2693-2701 [PMID: 21430069 DOI: 10.1158/1078-0432.CCR-10-2203]

24 **Ferrari F**, Reis MA. Study of risk factors for gastric cancer by populational databases analysis. *World J Gastroenterol* 2013; **19**: 9383-9391 [PMID: 24409066 DOI: 10.3748/wjg.v19.i48.9383]

25 **Lu J**, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. *Nature* 2005; **435**: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]

26 **Frampton AE**, Krell J, Kazemier G, Giovannetti E. Serum miR-1290 as a marker of pancreatic cancer--letter. *Clin Cancer Res* 2013; **19**: 5250-5251 [PMID: 23888071 DOI: 10.1158/1078-0432.CCR-13-1620]

27 **Hirata H**, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. *PLoS One* 2012; **7**: e51056 [PMID: 23226455 DOI: 10.1371/journal.pone.0051056]

28 **Swierniak M**, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M, Koperski L, de la Chapelle A, Jazdzewski K. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2013; **98**: E1401-E1409 [PMID: 23783103 DOI: 10.1210/jc.2013-1214]

29 **Xu Q**, Dong QG, Sun LP, He CY, Yuan Y. Expression of serum miR-20a-5p, let-7a, and miR-320a and their correlations with pepsinogen in atrophic gastritis and gastric cancer: a case-control study. *BMC Clin Pathol* 2013; **13**: 11 [PMID: 23521833 DOI: 10.1186/1472-6890-13-11]

30 **Świerniak M,** Świerniak A. The Role and Use of MicroRNA in Cancer Diagnosis. Intelligent Systems in Technical and Medical Diagnostics: Springer. 2014: 225-233 [DOI: 10.1007/978-3-642-39881-0\_18]

31 **Sanfiorenzo C**, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P, Hofman P. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. *PLoS One* 2013; **8**: e54596 [PMID: 23342174 DOI: 10.1371/journal.pone.0054596]

32 **Fang Y**, Feng Y, Wu T, Srinivas S, Yang W, Fan J, Yang C, Wang S. Aflatoxin B1 negatively regulates Wnt/β-catenin signaling pathway through activating miR-33a. *PLoS One* 2013; **8**: e73004 [PMID: 24015284 DOI: 10.1371/journal.pone.0073004]

33 **Kim WK**, Yang HK, Kim H. MicroRNA involvement in gastrointestinal stromal tumor tumorigenesis. *Curr Pharm Des* 2013; **19**: 1227-1235 [PMID: 23092343]

34 **Takane K**, Kanai A. Vertebrate virus-encoded microRNAs and their sequence conservation. *Jpn J Infect Dis* 2011; **64**: 357-366 [PMID: 21937815]

35 **Li JY**, Jia S, Zhang WH, Zhang Y, Kang Y, Li PS. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes. *Asian Pac J Cancer Prev* 2013; **14**: 3197-3203 [PMID: 23803104 DOI: 10.7314/APJCP.2013.14.5.3197]

36 **Giles KM**, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. *Biochem Biophys Res Commun* 2013; **430**: 706-710 [PMID: 23206698 DOI: 10.1016/j.bbrc.2012.11.086]

37 **Avci CB**, Harman E, Dodurga Y, Susluer SY, Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. *Asian Pac J Cancer Prev* 2013; **14**: 765-768 [PMID: 23621234 DOI: 10.7314/APJCP.2013.14.2.765]

38 **Ayaz L**, Görür A, Yaroğlu HY, Ozcan C, Tamer L. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. *J Cancer Res Clin Oncol* 2013; **139**: 1499-1506 [PMID: 23817697 DOI: 10.1007/s00432-013-1469-2]

39 **Yang L**, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. *Oncol Rep* 2012; **28**: 592-600 [PMID: 22614869 DOI: 10.3892/or.2012.1823]

40 **An IS**, An S, Kwon KJ, Kim YJ, Bae S. Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells. *Oncol Rep* 2013; **29**: 523-528 [PMID: 23152132 DOI: 10.3892/or.2012.2136]

41 **Wu X**, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer Prev Res* (Phila) 2013; **6**: 196-205 [PMID: 23466817 DOI: 10.1158/1940-6207.CAPR-12-0276]

42 **Wong AM**, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. *Cancer* 2012; **118**: 698-710 [PMID: 21720996 DOI: 10.1002/cncr.26309]

43 **Li P**, Ling Z, Zhao J, Yang H, Huang Y, Zhao M, Dong Z. [Establishment of cDNA microarray technology and analysis of gene expression profiles in human esophageal cancer cell line ECa109]. *Sheng Wu Yi Xue Gong Cheng Xue Za Zhi* 2008; **25**: 413-418 [PMID: 18610633]

44 **Xie J,** Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, Gui QJ, Zhang L, Li GQ. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. *Oncol Rep* 2014; **31:** 1715-1722 [PMID: 24573489 DOI: 10.3892/or.2014.3052]

45 **Tölle A**, Jung M, Rabenhorst S, Kilic E, Jung K, Weikert S. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. *Oncol Rep* 2013; **30**: 1949-1956 [PMID: 23877086 DOI: 10.3892/or.2013.2621]

46 **Golan K**, Vagima Y, Goichberg P, Gur-Cohen S, Lapidot T. MT1-MMP and RECK: opposite and essential roles in hematopoietic stem and progenitor cell retention and migration. *J Mol Med* (Berl) 2011; **89**: 1167-1174 [PMID: 21842347 DOI: 10.1007/s00109-011-0792-9]

47 **Furumoto K**, Arii S, Mori A, Furuyama H, Gorrin Rivas MJ, Nakao T, Isobe N, Murata T, Takahashi C, Noda M, Imamura M. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. *Hepatology* 2001; **33**: 189-195 [PMID: 11124835]


48 **Stenzinger A**, von Winterfeld M, Rabien A, Warth A, Kamphues C, Dietel M, Weichert W, Klauschen F, Wittschieber D. Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. *Hum Pathol* 2012; **43**: 1314-1321 [PMID: 22397871 DOI: 10.1016/j.humpath.2011.10.012]

49 **Li N**, Tang B, Zhu ED, Li BS, Zhuang Y, Yu S, Lu DS, Zou QM, Xiao B, Mao XH. Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. *FEBS Lett* 2012; **586**: 722-728 [PMID: 22321642 DOI: 10.1016/j.febslet.2012.01.025]


50 **Xue Q**, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN. *World J Gastroenterol* 2013; **19**: 9307-9317 [PMID: 24409057 DOI: 10.3748/wjg.v19.i48.9307]

**P-Reviewer:** Jonaitis L **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Figure 1 Differential expression of microRNAs in gastric cancer cells.** A: microRNAs (miRNA) expressions in gastric cancer cell lines SGC-7901 and MGC-803 were compared with the normal GES-1 cell line using cluster analysis. All cell samples were detected in triplicate, such that the nine lanes include GES-1 (G1-G3), SGC-7901 (S1-S3) and MGC-803 (M1-M3). The color scale denotes the extent of relative upregulation (red) and downregulation (green); B: Histogram of miR-374b-5p expression detected by cluster analysis; C: Confirmation of miR-374b-5p expression *via* quantitative real-time reverse-transcription polymerase chain reaction *(n* = 3); a*P* < 0.05 *vs* GSE-1.



**Figure 2 Effects of miR-374b-5p on MGC-803 cell metastasis and invasion.** MGC-803 cells were transfected with a miR-374b-5p antisense oligonucleotide or negative control-oligo vector, or treated with phosphate-buffered saline (untreated), or transfection reagent only. A: Cells were subjected to a transwell invasion assay and detected at 48 h after seeding (left: Coomassie Brilliant Blue stain, × 200; right, quantification); B: Wound margin distance was measured after 48 h in a scratch assay (Coomassie Brilliant Blue stain, × 40); C: Absorbances in a cell counting kit-8 assay 96 h after transfection; (*n* = 3), a*P* < 0.05 *vs* Anti-miR-374b-5p.



**Figure 3** **Regulation of RECK expression in MGC-803 cells by miR-374b-5p.** A: The miR-374b-5p binding site within the 3′ UTR of human (hsa) RECK cDNA was predicted by PicTar, TargetScan and miRanda software; B: Cells were co-transfected with RECK 3'UTR-pmirGLO and a plasmid containing either miR-374b-5p or miR-NC plasmid, a*P* < 0.05 *vs* miR-NC (*n* = 3); Results from C: Western blotting of protein; D: qRT-PCR from cells transfected for 48 h with anti-miR-374b-5p or a negative control vector, or treated with phosphate-buffered saline (untreated), or transfection reagent only; (*n* = 3), c*P* < 0.05 *vs* Anti-miR-374b-5p.

